1676 related articles for article (PubMed ID: 32348166)
1. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
3. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
Rossi GP; Sanga V; Barton M
Elife; 2020 Apr; 9():. PubMed ID: 32250244
[TBL] [Abstract][Full Text] [Related]
4. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
5. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.
Li J; Wang X; Chen J; Zhang H; Deng A
JAMA Cardiol; 2020 Jul; 5(7):825-830. PubMed ID: 32324209
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
[TBL] [Abstract][Full Text] [Related]
7. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
8. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
9. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
11. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study].
Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B
Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120
[TBL] [Abstract][Full Text] [Related]
12. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
[TBL] [Abstract][Full Text] [Related]
13. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Pirola CJ; Sookoian S
J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
[TBL] [Abstract][Full Text] [Related]
14. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G
Mayo Clin Proc; 2020 Jun; 95(6):1222-1230. PubMed ID: 32376099
[TBL] [Abstract][Full Text] [Related]
16. Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?
Selçuk M; Çınar T; Keskin M; Çiçek V; Kılıç Ş; Kenan B; Doğan S; Asal S; Günay N; Yıldırım E; Keskin Ü; Orhan AL
Clin Exp Hypertens; 2020 Nov; 42(8):738-742. PubMed ID: 32569491
[TBL] [Abstract][Full Text] [Related]
17. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
18. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
Albini A; Di Guardo G; Noonan DM; Lombardo M
Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
[TBL] [Abstract][Full Text] [Related]
19. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
[TBL] [Abstract][Full Text] [Related]
20. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
Tsioufis C; Dimitriadis K; Tousoulis D
Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
